|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Pharma Should Embrace Data Transparency: Sanofi (France) (SAN.PA) Exec
12/5/2012 7:31:16 AM
Sanofi's chief strategy officer David-Alexandre Gros has said the pharmaceutical industry should have nothing to fear about publishing raw data from clinical trials, a stance not shared by a number of drugmakers. The Financial Times Global Pharmaceutical and Biotechnology conference in London burst into life when one of the panel discussions turned to the topic of companies publishing complete raw datasets from their clinical trials. The spotlight has been on the latter of late, driven by campaigners such as the BMJ, the Cochrane Collaboration and Bad Pharma author Ben Goldacre, with increasing calls for public access to trial outcomes, whether they are positive or negative. Mr Gros was taking part in a discussion on new operating models for pharma with David Morris, global head development franchise, primary care at Novartis, and Jane Griffiths, company chairman of Janssen Europe, Middle East and Africa. When the debate turned to the issue of clinical trial transparency, Mr Morris said the release of raw data was a "challenging" issue that has to be managed appropriately.
|
|
|
|
|
|
|
|
|
|
|